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Abstract
According to the World Health Organization (2005), cardiovascular disease
(CVD) is the number one cause of death in most countries. Assessing a patient’s risk for
heart disease may include incorporating factors such as their gender, age, weight, tobacco
history, cholesterol, blood pressure, family history, and more recently, genetics.
Genome-wide association studies (GWAS) have made it possible to identify risk loci for
many of the common, complex disorders, including coronary artery disease (CAD). As
the medical genetics community undergoes a shift from a genetics focus to a genomics
oriented focus, genomic medicine is becoming more accessible. Research has begun to
examine how individuals perceive and utilize genomic information; however, little has
been done to explore preliminary feelings towards personalized genomic medicine in
those with a family history of heart disease alone.
This study explores the perceived utility of genomic testing in individuals with a
family history of heart disease and begins to define a role for genetic counselors within
the genomic medicine context. Individuals 18 years of age or older with at least one firstdegree or two second-degree relatives with heart disease were invited to participate. An
online questionnaire was distributed to patients at a local cardiology clinic, students at a
local university, and through Facebook.
A total of 29 participants met eligibility criteria and completed 80% or more of
the questionnaire. Frequencies, means, and standard deviations were calculated. Our
results indicate that our study population had low genetic literacy. After viewing a
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genetic information video, most participants perceived genomic information to be useful
in understanding their risk of developing heart disease. Most participants also believed
that a genetic counselor would be helpful in explaining not only genomic test results, but
also one’s risk for developing heart disease and medical management options. Lastly,
respondents typically indicated they were more likely to exercise regularly than engage in
diet modifications, take prescription medications, or regularly follow-up with a specialist
if their risk for heart disease was increased because of genetics.
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Chapter 1. Background
1.1 Overview of Cardiovascular Disease
According to the World Health Organization (2005), cardiovascular disease
(CVD) is the number one cause of death in most countries. It is a disease affecting the
heart and blood vessels. Many of the complications of cardiovascular disease are
associated with atherosclerosis (American Heart Association, 2016). Atherosclerosis,
also called coronary heart disease (CHD) or coronary artery disease (CAD), affects the
arteries that bring oxygenated blood to the heart (National Heart, Lung, and Blood
Institute, 2015). It occurs when plaque accumulates along the arterial walls (American
Heart Association, 2016). This plaque can continue to accumulate over time, and
eventually it will either harden or burst. Plaque that hardens will narrow the arteries,
restricting blood flow, and plaque that bursts can result in the formation of a blood clot
that restricts blood flow (National Heart, Lung, and Blood Institute, 2015).
When blood flow to the heart becomes restricted, it can cause chest pain or
myocardial infarction. Eventually, CHD can result in heart failure or arrhythmias due to
a weakened heart muscle.

Recommendations for preventing and treating CHD include

making lifestyle modifications to address obesity, taking statins, which lower cholesterol,
and possibly undergoing necessary surgical procedures (National Heart, Lung, and Blood
Institute, 2015; American Heart Association, 2013).
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Assessing a patient’s risk for CVD may include incorporating factors such as their
gender, age, weight, use of tobacco products, cholesterol, blood pressure, and family
history (Anderson, Odell, Wilson, & Kannel, 1991; Backer et al., 2003; Conroy et al.,
2003; Murabito et al., 2005; Nasir et al., 2004). In addition, it is possible to incorporate
certain genetic variants into a patient’s risk assessment for CVD. One single gene
condition associated with early-onset CVD is familial hypercholesterolemia (FH). This
condition results in poor metabolism of low-density lipoprotein (LDL), which is a type of
cholesterol found in the body. The frequency of this condition in Western countries is
believed to be around 1 in 400 to 1 in 500 (Austin, Hutter, Zimmern, & Humphries,
2004). Management of this condition for adults requires decreasing the risk factors
associated with coronary artery disease (CAD). This includes engaging in exercise
regularly, eating a healthy diet and managing one’s weight, quitting smoking, treating
high blood pressure, taking statins potentially in addition to other medications to decrease
lipid levels, taking a low-dose aspirin for those at high risk, and possibly referring to a
lipid specialist. Children with FH are recommended to engage in the same healthy
lifestyle activities as adults and see a lipid specialist. Children with this condition may
begin statin therapy starting at about eight years of age. When left untreated, affected
men have a 50% chance of experiencing a coronary event, either fatal or non-fatal, by 50
years of age. For untreated woman, this risk is 30% by 60 years of age (Youngbloom &
Knowles, 2016).
In addition, genome-wide association studies (GWAS) are being used to identify
risk loci for many of the common, complex disorders including coronary artery disease
(Jostins & Barrett, 2011). The variants, or SNPs, found in GWAS confer a modest effect
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(Bodmer & Bonilla, 2008; Ding, Bailey, & Kullo, 2011). However, in one study,
researchers determined that including genetic information at 11 SNPs into the
Framingham Risk Score resulted in a significant reclassification of the approximate 10year risk for CHD (Ding, Bailey, & Kullo, 2011). More recently, the Myocardial
Infarction Genes, or MI-GENES, clinical trial utilized genotype information from 28
SNPs associated with increased susceptibility for CHD to investigate whether genetic risk
for CHD affects health outcomes. In this trial, researchers utilized 28 SNPs to create
genetic risk scores (GRS). After incorporating the GRS into the total CHD risk, risk
approximations in the high GRS group rose by at least 10% (Kullo et al., 2016).
Further evidence for the genetic basis of CAD is that this condition clusters within
families. This familial clustering suggests that genetics contribute to the development of
this condition. Twin studies have been used to estimate the heritability of this disease.
According to these large studies, the heritability of CAD is estimated to be about 50% to
60%. Similarly, the heritability of myocardial infarction is estimated to be about 50% to
60% (Dai, Wiernek, Evans, & Runge, 2016). Given what has been uncovered about the
etiology of heart disease, it is undeniable that a genetic basis for this condition exists.
1.2 Personalized Genomic Medicine
Within the field of medical genetics, there is an ongoing shift from a narrower
genetics focus to a broader genomics focus (Collins and Guttmacher, 2001). Genomic
medicine is defined as “the diagnosis, optimized management, and treatment of disease –
as well as screening, counseling, and disease gene identification – in the context of
information provided by an individual patient’s personal genome.” (Boone, Wiszniewski,
& Lupski, 2011). The Human Genome Project and the International Haplotype Map
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have made it possible to perform GWAS studies (Morton, 2008). As such, genomic
medicine is becoming more accessible. Some healthcare providers will incorporate a
patient’s genomic information to help guide disease management. In the past, direct-toconsumer genetic testing companies have included analyzing complex diseases in their
tests (Marshall, 2011; Kaufman et al., 2012). Personalized medicine can be used to
provide a risk assessment for complex diseases and help guide decision-making regarding
which therapy to pursue (Mills, Barry, & Haga, 2014). The aim of personalized medicine
is to incorporate an individual’s genomic data (as well as other relevant variables) into
their clinical evaluation to more effectively guide that individual’s medical management
(Abul-Husn, Owusu Obeng, Sanderson, Gottesman, Scott, 2014).
While there is a potential for genomic medicine to give patients information they
can preemptively act upon to improve their health, how genomic test results are received
and utilized by patients continues to be investigated. It has been found that when
compared to a control group without a genetic predisposition for cardiovascular disease,
individuals with a single-gene genetic predisposition (FH) believe medication to be more
effective, but they do not differ with the control group in terms of the perceived
effectiveness of living a healthy life or engaging in preventive behavior (Claassen et al.,
2012). In terms of providing genomic information to individuals, it has been shown that
although participants generally understand genomic risk information, they more
frequently remember results indicating an increased risk or those they are particularly
interested in (Gordon et al., 2012). Most undergoing genomic testing say that a desire to
improve their health was the primary reason they pursued genomic testing (Gollust et al.,
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2012; Su et al., 2011), but it has been shown that not all change their lifestyle or discuss
their results with their physician (Gordon et al., 2011).
However, the MI-GENES clinical trial found a somewhat different result. When
providing participants with a 10-year probability of developing CHD using either a
conventional risk score (CRS) or a conventional risk score and genetic risk score (GRS),
those that received genetic risk information had lower LDL-C levels at 6 months than
those who received just the CRS. The difference between the groups in terms of LDL-C
levels was due to initiation of statin therapy. Although presentation of genetic risk
information resulted in initiation of statin therapy, after a discussion with a physician,
there were no differences in dietary fat intake, exercise, or level of anxiety between the
two groups. This indicates that those at genetic risk may be willing to engage in medical
interventions to reduce their risk of developing CHD, but making lifestyle modifications
may be more difficult for them (Kullo et al., 2016).
Genomic risk information not only affects a patient’s behavior and medical
management; it also has psychological effects. Families and individuals affected with
cardiogenetic conditions report a mix of psychological stressors (i.e., guilt about passing
on the condition, isolation, and anxiety) and positive results (i.e., resolution and a positive
attitude). For families and individuals receiving genetic testing or personalized genomic
medicine, it may be helpful to provide psychological counseling You’rto address these
stressors that may arise (Hidayatallah et al., 2014).
1.3 Genetic Counseling within the Personalized Genomic Medicine Context
In the past, direct-to-consumer (DTC) genetic tests provided consumers with a
risk assessment of certain complex diseases based on the consumer’s genomic
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information. Members of the public frequently misinterpreted genomic DTC results even
though they considered these results to be straightforward. In addition, the public
thought these results would be more beneficial in guiding their medical management than
genetic counselors did. This indicates that patients receiving genomic test results may
need assistance to interpret the meaning and utility of these results correctly (Leighton,
Valverde, & Bernhardt, 2011).
When genetic counselors provide genomic risk information, it is typically
associated with positive results. In one study, participants receiving genomic risk
information for Type 2 Diabetes Mellitus reported greater trust in the results if a genetic
counselor provided them (Mills, Barry, & Haga, 2014). In addition, the MI-GENES
clinical trial assessed how presentation of CHD genetic risk information by a genetic
counselor affected perceived personal control and genetic counseling satisfaction as a
secondary study. In this study, all participants received their CHD risk from a genetic
counselor. In comparison to those receiving a conventional risk score only, those who
received a genetic risk score in addition to a conventional risk score reported greater
perceived personal control and genetic counseling satisfaction. This result indicates that
patients want to be receiving CHD genetic risk information and report greater genetic
counseling satisfaction when they do receive this information (Robinson et al., 2015).
The genetic counseling approach of facilitating open communication while
integrating disease information with psychosocial counseling leads to greater
empowerment and self-efficacy for patients. These effects may lead to behavior change
(Inglis et al., 2015). Therefore, genetic counselors may be useful in the process of
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relaying information regarding common complex diseases in such a way that would result
in positive lifestyle changes (Austin, 2015).
In one prospective study, researchers aimed to develop feedback strategies for
genomic test results for genetic counselors and other healthcare professionals. They
asked 60 women diagnosed with breast cancer at a young age (40 or younger) in semistructured interviews what information they would like to receive when genomic test
results are disclosed. They found that those who participated were most interested in the
possible health impact associated with a variant. They were interested in the healthrelated implications of variants for both themselves and their family members.
Participants also wanted to know the quantitative risk associated with a variant and the
variant’s prevalence in the population. Regarding variants increasing risk for
preventable/treatable disorders, interviewees were most interested in education on
decreasing their risk, preventing the condition, or treating the condition (Seo et al., 2016).
Although this study examined this topic in individuals diagnosed with breast cancer at a
young age, the majority opinion regarding variants associated with preventable or
treatable disorders can be applied to CHD.
1.4 Genetic Counselors as Genomic Counselors
Genetic counseling is the process of helping people understand and adapt to
the medical, psychological and familial implications of genetic contributions
to disease. This process integrates:
•

Interpretation of family and medical histories to assess the chance of
disease occurrence or recurrence

•

Education about inheritance, testing, management, prevention,
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resources and research.
•

Counseling to promote informed choices and adaptation to the risk or
condition. (National Society of Genetic Counselors, N.D.)

Genetic counselors are trained in the scientific principles of genetics,
communication, risk evaluation, and incorporating a patient-focused approach into their
practice (O’Daniel, 2010). They have been described as useful in recording family
histories, discussing inheritance and clinical features of a condition, and addressing
psychosocial concerns related to heritable conditions. They also discuss genetic testing
including the different types of results, limitations, and benefits as well as risks of testing
(Hershberger, Cowan, Morales, & Siegfried, 2009). Therefore, genetic counselors are the
ideal professionals to not only explain the inheritance of complex diseases, such as heart
disease, but also to consent for genomic testing and discuss the potential implications of
undergoing this type of expansive testing.
As such, genetic counselors are excellent candidates to play a pivotal role in
integrating genomic disease risks into the healthcare field. Within the genomic medicine
context, genetic counselors are an appropriate choice for facilitating testing, interpreting
results, speaking with patients about their risk assessment, addressing the limitations of
genomic testing, and providing information to the public (O’Daniel, 2010).
The National Society of Genetic Counselors (NSGC) also sees the value of the
genetic counselor’s role in the genomic era. They have created a Personalized Medicine
Special Interest Group (SIG) (Mills & Haga, 2014). This special interest group is now
called the Precision Medicine SIG (NSGC, 2017). In addition, the 35th Annual Education
Conference was titled “A Landmark in Genomics: Our Value in Healthcare.” In the 2012
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NSGC Professional Status Survey, 1.2% of genetic counselors included in the survey
indicated that they have a specialty in genomic medicine or personal genomics/genomic
profiling (NSGC, 2012, as cited in Mills & Haga, 2014). An updated value could not be
found for 2016.
This new era of genomic testing will demonstrate a shift from reactive testing
with the purpose of determining a diagnosis for mostly single-gene disorders to proactive
large-scale testing to prevent complex diseases. Genomic counseling will deviate from
the traditional model of genetic counseling in: “1) the number and/or type of diseases for
which testing is available and discussed, 2) purpose of testing, 3) intervention and clinical
utility and 4) access to testing” (Mills & Haga, 2014). The type of patient for which
genetic testing is ordered may also differ. In typical genetic counseling, those
undergoing genetic testing either have a genetic condition or are at risk for having
inherited a genetic condition. This may also be the case for those pursuing large-scale
genome testing; however, patients with no health complications or family history may
have this testing too (Patel et al., 2013).
Genomic counselors will also be filling expanded roles. One of the key areas in
which role expansion is predicted is in health promotion whose aim is to reduce the
chance of developing a disease. In addition to helping individuals comprehend the
genetic and environmental basis of risk, counselors may also discuss prevention
information, screening, and further suggestions to inspire engagement in preventive
behavior (Mills & Haga, 2014). Motivational counseling, which is more directive, will
likely be useful in helping patients follow behavior modifications and comply to
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treatment recommendations, in addition to bettering health outcomes (Hettema, Steele, &
Miller 2005, as cited in Mills & Haga, 2014).
Studies have begun publishing recommendations for “genomic counseling.”
Following a case where a genetic counselor and medical geneticist provided genomic
counseling for a patient after direct to consumer (DTC) genetic testing, two authors
suggested practice recommendations for this area of genetic counseling. The
recommendations included studying the genomic test results before the session takes
place and focusing on results of significance. They also suggest using resources, such as
primary literature and other sources online (i.e., dbSNP), to further study genetic variants.
The creation of visual aids to provide education on complex genomic concepts was
encouraged. Lastly, the educational component is stressed for these types of sessions.
The authors suggested that “education should be a major component of genomic
counseling sessions, including the provision of additional resources for the patient to use
after the session” (Sturm & Manickam, 2012).
Recognizing the suitability of the genetic counseling profession in providing
genomic counseling, studies are starting to be published addressing how to train both
students and working professionals to enter this new era of medicine (Hooker, Ormond,
Sweet & Biesecker, 2014). In addition, many program directors recognize the need to
incorporate genomic medicine topics into genetic counseling program curricula. Most
program directors believe it is important to incorporate the topic of genomics into genetic
counseling training courses. In addition, during interviews, program directors used
adjectives like “critical” and “vital” when addressing the importance of training students
for genomic counseling (Profato, Gordon, Dixon, & Kwan, 2014). Within these
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programs, students should gain observation and experience to be exposed to the nuances
of genomic counseling (Mills & Haga, 2014).
1.5 Value of Study
Currently, the medical genetics community is shifting from a genetics focus to a
genomics orientation (Collins and Guttmacher, 2001). Investigations on how patients
receive and utilize genomic results have begun (Gordon et al., 2012; Kullo et al., 2016).
Scientists have also begun to investigate the benefits of using a genetic counselor to
explain genetic risk information for complex diseases (Mills, Barry, & Haga, 2014);
however, there are still some gaps in the literature. First, there is little research on
presenting a genomic risk assessment to patients at high risk for cardiovascular disease.
Until the MI-GENES Clinical Trial was published last year, patient response to
knowledge of the complex genetics of cardiovascular disease went largely uninvestigated
in the literature (Kullo et al., 2016). Whereas there has been literature exploring personal
utility after receiving genome test results and literature exploring how health messages
about genetic risk for common conditions affect perception of susceptibility in the public,
little has been done to explore preliminary feelings towards personalized genomic
medicine in individuals with a family history of heart disease (Lewis et al., 2015;
Smerecnik et al., 2009). Therefore, exploring whether those with a family history of
heart disease find genomic information beneficial and of use would further add to our
knowledge of the public perception of personalized genomic medicine.
This study explores the perceptions of individuals with a family history of
cardiovascular diseases in regard to genetic risk factors associated with heart conditions,
such as coronary heart disease. This study has four goals: (1) to assess individuals’
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understanding of the genetic basis of heart disease, (2) to determine whether these
individuals think personalized genomic medicine would be helpful in assessing their risk
of developing heart disease, (3) to identify the genetic counselor’s role in providing
genomic risk information, and (4) to determine whether these individuals intend to make
lifestyle modifications having learned about the genetic basis of heart disease. This
exploratory research provides insight into the perceived utility of genomic testing for
individuals with a family history of a complex disease. In addition, it begins to define a
role for genetic counselors within a genomic medicine context.
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Chapter 2. The Perceived Utility of Personalized Genomic Medicine in Individuals
with a Family History of Heart Disease: A Pilot Study

2.1 Abstract
According to the World Health Organization (2005), cardiovascular
disease (CVD) is the number one cause of death in most countries. Assessing a patient’s
risk for heart disease may include incorporating factors such as their gender, age, weight,
tobacco history, cholesterol, blood pressure, family history, and more recently, genetics.
Genome-wide association studies (GWAS) have made it possible to identify risk loci for
many of the common, complex disorders, including coronary artery disease (CAD). As
the medical genetics community undergoes a shift from a genetics focus to a genomics
oriented focus, genomic medicine is becoming more accessible. Research has begun to
examine how individuals perceive and utilize genomic information; however, little has
been done to explore preliminary feelings towards personalized genomic medicine in
those with a family history of heart disease alone.
This study explores the perceived utility of genomic testing in individuals with a
family history of heart disease and begins to define a role for genetic counselors within
the genomic medicine context. Individuals 18 years of age or older with at least one firstdegree or two second-degree relatives with heart disease were invited to participate. An
online questionnaire was distributed to patients at a local cardiology clinic, students at a
local university, and through Facebook.
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A total of 29 participants met eligibility criteria and completed 80% or more of
the questionnaire. Frequencies, means, and standard deviations were calculated. Our
results indicate that our study population had low genetic literacy. After viewing a
genetic information video, most participants perceived genomic information to be useful
in understanding their risk of developing heart disease. Most participants also believed
that a genetic counselor would be helpful in explaining not only genomic test results, but
also one’s risk for developing heart disease and medical management options. Lastly,
respondents typically indicated they were more likely to exercise regularly than engage in
diet modifications, take prescription medications, or regularly follow-up with a specialist
if their risk for heart disease were increased because of genetics.
2.2 Introduction
According to the World Health Organization (2005), cardiovascular disease
(CVD) is the number one cause of death in most countries. It is a disease affecting the
heart and blood vessels. Many of the complications of CVD are associated with
atherosclerosis (American Heart Association, 2016). Atherosclerosis, also called
coronary heart disease (CHD) or coronary artery disease, affects the arteries that bring
oxygenated blood to the heart (National Heart, Lung, and Blood Institute, 2015). It
occurs when plaque accumulates along the arterial walls (American Heart Association,
2016). This plaque can continue to accumulate over time, and eventually it will either
harden or burst. Plaque that hardens will narrow the arteries, restricting blood flow, and
plaque that bursts can result in the formation of a blood clot that restricts blood flow
(National Heart, Lung, and Blood Institute, 2015).
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Assessing a patient’s risk for CVD may include incorporating factors such as
their gender, age, weight, use of tobacco products, cholesterol, blood pressure, and family
history (Anderson, Odell, Wilson, & Kannel, 1991; Backer et al., 2003; Conroy et al.,
2003; Murabito et al., 2005; Nasir et al., 2004). In addition, it is possible to incorporate
certain genetic variants into a patient’s risk assessment for CVD. One single gene
condition associated with early-onset CVD is familial hypercholesterolemia (FH). This
condition results in poor metabolism of low-density lipoprotein (LDL), which is a type of
cholesterol found in the body (Austin, Hutter, Zimmern, & Humphries, 2004). When left
untreated, affected men have a 50% chance of experiencing a coronary event, either fatal
or non-fatal, by 50 years of age. For untreated woman, this risk is 30% by 60 years of
age (Youngbloom & Knowles, 2016).
Additionally, GWAS studies have identified SNPs that confer a modest effect
contributing to common complex disorders (Jostins & Barrett, 2011; Bodmer & Bonilla,
2008). SNPs stands for single nucleotide polymorphisms (Kullo et al., 2016). A recent
clinical trial that aims to assess whether genetic susceptibility for CHD affects health
outcomes, the MI-GENES Clinical Trial, utilized 28 SNPs to create genetic risk scores
(GRS). In this trial, after incorporating the GRS into the total CHD risk, risk
approximations in the high GRS group rose by at least 10% (Kullo et al., 2016). Both the
condition FH and this clinical trial provide evidence for a genetic basis to heart disease.
Given this, within the field of medical genetics, there is an ongoing shift from a
narrower genetics focus to a broader genomics focus (Collins and Guttmacher, 2001).
The aim of personalized medicine is to incorporate an individual’s genomic data (as well
as other relevant variables) into their clinical evaluation to more effectively guide that
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individual’s medical management (Abul-Husn, Owusu Obeng, Sanderson, Gottesman,
Scott, 2014). Personalized medicine can be used to provide a risk assessment for
complex diseases and help guide decision-making regarding which therapy to pursue
(Mills, Barry, & Haga, 2014).
Most undergoing genomic testing say that a desire to improve their health was the
primary reason they pursued genomic testing (Gollust et al., 2012; Su et al., 2011), but it
has been shown that not all change their lifestyle or discuss their results with their
physician (Gordon et al., 2011). However, the MI-GENES clinical trial found a
somewhat different result. When providing participants with a 10-year probability of
developing CHD using either a conventional risk score (CRS) or a conventional risk
score and genetic risk score (GRS), those that received genetic risk information had lower
LDL-C levels at 6 months than those who received just the CRS. The difference between
the groups in terms of LDL-C levels was due to initiation of statin therapy. Although
presentation of genetic risk information resulted in initiation of statin therapy, after a
discussion with a physician, there were no differences in dietary fat intake, exercise, or
level of anxiety between the two groups. This indicates that those at genetic risk may be
willing to engage in medical interventions to reduce their risk of developing CHD, but
making lifestyle modifications may be more difficult for them (Kullo et al., 2016).
When genetic counselors are the professionals providing genomic risk
information, it is typically associated with positive results. In one study, participants
receiving genomic risk information for Type 2 Diabetes Mellitus reported greater trust in
the results if a genetic counselor provided them (Mills, Barry, & Haga, 2014). In
addition, the MI-GENES clinical trial assessed how presentation of CHD genetic risk
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information by a genetic counselor affected perceived personal control and genetic
counseling satisfaction as a secondary study. In comparison to those receiving a
conventional risk score only, those who received a genetic risk score in addition to a
conventional risk score reported greater perceived personal control and genetic
counseling satisfaction. This result indicates that patients want to be receiving CHD
genetic risk information and report greater genetic counseling satisfaction when they do
receive this information (Robinson et al., 2015). As such, genetic counselors are
excellent candidates to play a pivotal role in integrating genomic disease risks into the
healthcare field (O’Daniel, 2010).
Recognizing the suitability of the genetic counseling profession in providing
genomic counseling, studies are starting to be published addressing how to train both
students and working professionals to enter this new era of medicine (Hooker, Ormond,
Sweet & Biesecker, 2014). Similarly, most program directors believe it is important to
incorporate the topic of genomics into genetic counseling training courses (Profato,
Gordon, Dixon, & Kwan, 2014). Within these programs, students should gain
observation and experience to be exposed to the nuances of genomic counseling (Mills &
Haga, 2014).
This present study is exploratory research that will provide insight into the
perceived utility of genomic testing for individuals with a family history of a complex
disease. In addition, it will begin to define a role for genetic counselors within a genomic
medicine context. Existing literature explores how complex genetic risk information is
received and utilized by those having undergone genomic testing, but none of these
studies investigate the pre-test perceived utility of this technology in individuals with a
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family history of heart disease alone (Gordon et al., 2012; Gollust et al., 2012; Kullo et
al., 2016). Addressing this question in the current study will broaden our understanding
of whether individuals at risk for complex diseases anticipate genomic medicine to be
useful. Moreover, although literature has begun to address the benefits of integrating the
process of genetic counseling into providing genetic risk assessment for complex
diseases, this study aims to directly address whether individuals prefer receiving these
results from a genetic counselor (Mills, Barry, & Haga, 2014).
Current research has also indicated that presentation of genomic risk information
does not lead to lifestyle modifications in a majority of participants (Gordon et al., 2011).
In the MI-GENES clinical trial, although the researchers found that the initiation of statin
therapy resulted in lower LDL-C levels in the group presented with a GRS, they also
found that there were no differences in dietary fat intake or exercise between those
presented with a GRS and those not presented with a GRS (Kullo et al., 2016). Through
assessing participants’ intention to change behavior following education of the genetic
risks associated with heart disease, we can generate a pre-genetic test measure of whether
participants are willing to change behavior. In addition, it will allow us to address the
question of how high a genetic risk would need to be to prompt the participants to engage
in health-related behavioral changes.
2.3 Materials and Methods
2.3.1 Study Population
This study surveyed individuals age 18 or older with a family history of heart
disease. Participants were required to have at least one first-degree relative or two
second-degree relatives with heart disease to participate in the survey developed on
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SurveyMonkey.com. Participants were excluded if they did not have at least one firstdegree or two second-degree relatives with heart disease. Eligibility was ascertained by a
series of questions at the start of the study. If participants did not meet eligibility criteria,
they were routed out of the survey using branch logic developed by SurveyMonkey.
Individuals with a family history and current heart disease were not excluded from the
study. Participants were offered the chance to take part in a drawing for one of five, $5
Amazon gift cards. All answers to questions were completely anonymous. Participants
were redirected to a separate survey to provide their email addresses if they were
interested in the opportunity to take part in the gift card drawing.
2.3.2 Survey Distribution
Information to take part in the study was provided to a local cardiology clinic,
Palmetto Heart, and to a local American Heart Association chapter. The clinic and
association were provided with a flyer and letter to participants (Appendix A and B) via
email. Students at a small liberal arts university in the Southeastern United States were
also invited to take part in the study. In addition, the survey was posted on both the
American Heart Association Facebook page as well as the principle investigator’s
personal Facebook. It was posted on the principle investigator’s Facebook wall and
shared by Facebook friends.
2.3.3 Instrumentation
An online questionnaire (Appendix C) was developed on SurveyMonkey.com.
The questionnaire was composed of primarily quantitative questions as well as a few
qualitative questions. One qualitative question was used to assess the participant’s intent
of sharing personalized heart disease genetic risk information with their family members.
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Another was asked to determine which healthcare providers participants thought would
be most helpful in explaining genomic test results and medical management. Question
and answer formats found in this questionnaire included multiple choice, comment box,
and Likert scale. A full set of the questions asked in the questionnaire can be found in
Appendix C. A participant consent agreement (Appendix D) was found on the first page
of the questionnaire. By pressing the “Next” button at the bottom of the page,
participants indicated their consent to participate in the study. The questionnaire was
designed with four goals in mind:
1). To assess participants’ baseline understanding of the genetic risk factors
associated with heart disease
2). To assess the perceived utility of genomic information for participants
3). To determine the genetic counselor’s role in providing genomic risk
information
4). To assess whether participants would intend to alter their lifestyle having
learned that genetics increased their risk for developing heart disease
After a series of questions determining eligibility, participants’ baseline
understanding of the genetic risks associated with heart disease was assessed. Following
this portion of the questionnaire, a link to a short educational video about the genetic
risks associated with heart disease was provided. The script to this video can be found in
Appendix E. Questions assessed the perceived utility of the information presented in the
video. Participants were asked to indicate if they would share genetic risk information
with family and doctors. A comment box was used so that participants could identify
those family members with whom they would share this information.
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Participants were then presented with a description of the genetic counseling
profession, cited from the National Society of Genetic Counselors. After this, questions
were asked to determine whether participants thought genetic counseling would be
helpful in understanding the genetic risk, genomic test results, and medical management
of heart disease. The participants were also asked to indicate other healthcare professions
that may be helpful in explaining genomic test results and their implications using a
comment box. Lastly, a Likert scale was utilized to assess participants’ intention to
undergo lifestyle modifications if they learned genetics alone increased their risk of
developing heart disease by 10%. As part of this section of the questionnaire, comment
boxes were used to determine the percent genetic risk at which participants would be
willing to alter their lifestyle.
The categorical order of questions was as follows: gauging background
knowledge of genetics, assessing the usefulness of the genomic risk information
presented in the genetic education video, determining the role of the genetic counselor
and other healthcare providers in discussing genomic risk information and management,
assessing intention to change lifestyle, and demographics. Demographic information
included the participant’s age, preferred gender, highest education level completed, and
current heart disease status (i.e., affected vs. unaffected). All information presented in
the questionnaire was used from references cited in the Background section.
2.3.4 Data Analysis
Both quantitative and qualitative questions from the questionnaire were analyzed
using descriptive statistics. Statistical Package for the Social Sciences 23.0 (SPSS) and
Excel 2016 were utilized to analyze quantitative data. Two sets of Likert scale questions
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can be found in this questionnaire. The first set was used to determine participants’
baseline understanding of the genetics of heart disease. For this question, answers were
chosen from a drop-down menu with all numbers between 0-10. A value of 0 indicated
0%, and a value of 10 indicated 100%. The second Likert scale was utilized to assess
participants’ intention to undergo lifestyle modifications if they learned genetics alone
increased their risk of developing heart disease by 10%. For this question, answers were
coded between 1 to 5, with a value of 1 indicating that the intention to change was very
likely, and a value of 5 indicating that the intention to change was unlikely.
Frequencies were calculated for all questions. Mean and standard deviations were
calculated when appropriate to address one of the four goals of this study. Chi-square
tests were used to determine relationships between questions; however, most results from
these tests were statistically insignificant. Pearson correlation tests did not show
statistically significant results. All Chi-square and Pearson Correlation tests were
analyzed and discussed using Laerd Statistics. Means and standard deviations were
reported as suggested in the APA Publication Manual.
The principal investigator coded qualitative data into themes. These themes were
reviewed by all committee members. Themes regarding which relatives participants
would share personal genomic information with and which providers would be helpful in
explaining this information were elucidated.
2.4 Results
2.4.1 Participant Demographics
Fifty people began the questionnaire; however, only 29 of these participants met
eligibility criteria and completed 80% of the survey or more (58.0%). Of these 29
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participants, 20.7% had relatives with heart disease on their mother’s side, 37.9% had
relatives with heart disease on their father’s side, and 41.4% had heart disease on both
sides of their family.
Most participants were female (65.5%). Participants were between 18-66 years of
age (M = 28.276, SD = 13.849). The majority of participants were unaffected with heart
disease (96.6%). All demographic information collected for these participants can be
found in Table 2.1.
2.4.2 Background Genetic Knowledge
Both a Likert scale and multiple choice questions were used to assess participants’
baseline knowledge of genetics. These questions had a particular emphasis on a
participant’s knowledge in relation to heart disease. The first two questions used a Likert
scale. This scale was presented as a drop-down menu containing all numbers between 010. In this scale, 0 equated to 0% and 10 equated to 100%. When asked what
participants thought the risk of heart attack was based on genetic factors, 34.5% indicated
a correct value of 5 or 6. The average value indicated was 6.655 (SD = 2.525). When
asked what the risk of atherosclerosis is based on genetic factors, 34.5% of participants
indicated a correct value of 5 or 6 (M = 6.552, SD = 2.213). Participants were also asked
to assess whether those with a family history of a single gene condition related to
coronary artery disease, called FH, are at higher, the same, or lower risk for developing
heart disease than those with a family history of heart attacks. Approximately 72% of all
participants accurately indicated that those with a family history of FH are at a higher risk
for heart disease than those with a family history of heart attacks.
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The last three questions of this section assessed participants understanding of the
genetic relatedness between various relatives. A minority of participants accurately
answered that having a sister with heart disease or a mother with heart disease would put
them at equal risk for developing the condition (27.6%). A total of 55.2% of participants
correctly answered that having a mother with heart disease would put them at greater risk
for developing the condition than having a grandmother with the condition. Similarly,
55.2% of participants accurately answered that having an aunt with heart disease would
put them at greater risk for the condition than having a cousin with heart disease.
None of the 29 participants answered all six background genetic knowledge
questions correctly. The average number of questions answered correctly was 2.793 (SD
= 1.236). A graphical representation of the frequencies of the number of correct answers
can be found in Figure 2.1.
2.4.3 Perceived Utility of Personalized Genomic Medicine
After watching a short genetic education video, participants were asked to specify
the usefulness of genomic information and the individuals with whom they would share
this information with. A total of 51.7% of participants strongly agreed that
genetic/genomic information would be useful for understanding their risk of developing
heart disease. In addition, 44.8% of participants agreed that genetic/genomic information
would be useful in understanding their risk for this condition. Only one stated a neutral
stance on this question (3.4%). No participants indicated that they disagreed or strongly
disagreed with the usefulness of this information.
Most participants indicated they would share this information with their doctor
(96.6%). Only one participant indicated they would not share this information with their
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physician (3.4%). Most participants also indicated they would share this information
with family members (96.6%). Again, only one participant indicated they would not
(3.4%).
When asked which family members participants would share this information
with, a couple of themes were identified. Answers that could not be easily coded into
immediate and extended family members were excluded from analysis. For instance,
participants who indicated they would share this information with “all” family members
were not included. Most participants would share this information with immediate
family members. A total of 79.3% participants specifically indicated they would share
this information with at least one of the following: a parent, a sibling, or children. A
majority of participants indicated they would share this information with their mother
and/or father. One participant noted:
[I] would share this information [with] my parents who do not already have great
knowledge about this subject. I would also share this information with other
family members that [may be] at high risk for heart problems in their later life,
and I along with them will discuss actions that we can take now [being young]
that will lower our chances or prevent our chances of heart problems in our later
life.
Most participants also indicated they would inform their siblings of this information.
Only seven participants indicated they would share this information with extended
family members. Some participants explicitly listed extended family members as with
whom they would share this with. These answers included grandmother, grandparent(s),
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aunts/uncles, and cousins. A few others listed they would share this information with
extended/non-immediate family members.
2.4.4. Genetic Counselors in the Genomic Context
After being provided with a description of the genetic counseling profession, cited
from the National Society of Genetic Counselors, participants were asked to indicate
which healthcare professionals would be helpful in understanding the risk for developing
heart disease, genomic test results, and medical management. When asked whether a
genetic counselor would be helpful to discuss a participants’ risk for heart disease, 82.8%
of participants indicated a genetic counselor would be helpful. A total of four
participants indicated they were unsure about this (13.8%), and one participant indicated
a genetic counselor would not be helpful in understanding this information (3.4%).
Additionally, 86.2% of participants indicated genetic counselors would be helpful in
explaining genomic/genetic test results. Only two participants indicated genetic
counselors would not be helpful in explaining these results (6.9%), and two participants
indicated they were unsure (6.9%). Participants were also asked to indicate whether
genetic counselors would be helpful in discussing management options related to heart
disease. Approximately 72% participants indicated that genetic counselors would be
helpful in discussing this topic. Only one participant indicated they would not (3.4%),
and 24.1% participants indicated they were unsure.
Participants were then asked to indicate other healthcare providers that would be
helpful in explaining genomic test results and discussing medical management. The
frequency of those that said a cardiologist or other specialist would be helpful in this
regard was 96.6%. A majority of participants also indicated that a geneticist would be
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helpful in explaining this information (72.4%). Fewer participants indicated a nutritionist
would be helpful in this regard (44.8%), and only 20.7% of participants indicated that a
nurse would be helpful in explaining this information. Participants were also asked to
indicate other providers that would be helpful in explaining genomic test results and
management. One participant indicated a primary care provider (3.4%), and one
participant indicated someone from the sports medicine, physical therapy field would be
helpful (3.4%). This information is summarized on Table 2.2.
2.4.5 Intention to Alter Lifestyle
Participants were asked the likelihood they would engage in the following
lifestyle modifications having learned that genetics alone increased their risk of
developing heart disease by 10%: change diet, exercise regularly, take prescription
medications, and regularly follow-up with a specialist. Most participants indicated their
intention to change diet was between probable to neutral (M = 2.069, SD = 1.25160). A
chi-square test for association was conducted between gender and likelihood of changing
diet. There was a statistically significant association between gender and likelihood of
changing diet, χ2(8) = 18.958, p = .015, with females being more likely to change diet
than males. Participants were more likely to engage in exercise regularly (M = 1.7931,
SD = 1.048). The average value for participants’ intention to take prescription
medications was 2.069 (SD = 1.132). The mean for participants’ intention to regularly
follow-up with a specialist was 2.036 (SD = 1.261). Frequencies for these Likert scale
questions can be found in Table 2.3.
The next set of questions asked how high participants’ genetic risk would have to
be for them to undergo lifestyle modifications. The mean percent value for how high
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genetic risk would have to be to warrant changes to diet was 41.041 (SD = 21.698). A
total of five participants gave non-numerical answers to this question; therefore, their
answers were not included in the quantitative analysis. The average percent value for
how high genetic risk would have to be for participants’ to be willing to regularly
exercise was 33.909 (SD = 24.102). A total of seven answers were excluded from
quantitative analysis due to non-numerical or unclear answers.
The mean percent value for the genetic risk at which participants indicate they
would be willing to take prescription medications was 47.917 (SD = 26.137). This
quantitative analysis excluded five non-numerical answers. Lastly, the average genetic
risk percent value at which participants would be willing to regularly follow-up with a
specialist was 44.250 (SD = 23.988). A total of five participants gave non-numerical
answers for this question and were therefore excluded from quantitative analysis. A
summary of these findings can be found in Table 2.4.
2.5 Discussion
This study explored the perceived utility of personalized genomic medicine in
those with a family history of heart disease. This study had four goals in mind. The first
goal was to assess participants’ baseline understanding of general genetics and genetic
risk factors associated with heart disease. The second was to assess whether participants
perceive utility in genomic information. Third, this study sought to determine the genetic
counselor’s role in providing genomic risk information. Lastly, this study attempted to
understand whether participants would intend to alter their lifestyle having learned that
genetics increased their risk of developing heart disease.
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Overall, participants tended to overestimate the risk genetic factors confer for
different heart conditions. According to previous research, the heritability of coronary
artery disease and myocardial infarction was estimated to be between 50% and 60% (Dai,
Wiernek, Evans, and Runge, 2016). However, in this study, the average value
participants indicated for the risk of a heart attack based on genetic factors was 66.55%.
Similarly, the mean value participants indicated for the risk of atherosclerosis based on
genetic factors was 65.52%. Although participants tended to overestimate the genetic
risk factors for multifactorial heart conditions, according to our research, most
participants understood that a family history of a Mendelian condition, FH, confers a
greater risk for heart disease than a family history of heart attacks.
The genetic relatedness between various relatives seemed to be a confusing point
for many participants. Most were able to correctly assess that a mother is more
genetically related than a grandmother and that an aunt is more genetically related than a
cousin. However, only 27.6% of participants were able to accurately determine that a
sister and mother are equally genetically related.
Out of all six questions asked in the section assessing background genetic
knowledge, none of the participants were able to answer all six questions correctly. In
fact, the average number of questions answered correctly was 2.793. This is less than
50% of the questions asked. These results indicate that the baseline genetic literacy of
this surveyed population was rather low.
Following the viewing of an educational video about the genetic risk associated
with heart disease, 96.5% of participants either agreed or strongly agreed that
genetic/genomic information would be helpful in understanding their risk. Previous

29

research has found similar results. In a study of patients with inflammatory bowel
disease (IBD), researchers found that participants perceive usefulness in genetic testing
for understanding the causes of IBD and risk to other family members (Hooker et al.,
2014). Our results, although in a population chosen based on family history as opposed
to personal disease history, largely found genetic information to be helpful in
understanding personal risk in the context of a family history of heart disease.
Most participants in the present study indicated they would share these results
with their doctor. Previous research has shown that most undergoing genomic testing say
that a desire to improve their health was the primary reason they pursued this testing
(Gollust et al., 2012; Su et al., 2011), but it has been shown that not all discuss results
with their physician (Gordon et al., 2011). In a study by Gordon et al. (2011), 25 out 60
of their participants shared risk results for multifactorial diseases, which included
genomic risk information, with their physician. Another 14 participants indicated they
had not seen their physician since they had received their results, but that they intended to
share them. Although 96.6% of participants in our study indicate they intend to share
results with their physician should they undergo genomic testing, whether or not they
would follow through with this claim cannot be confirmed. Further research on this topic
is warranted.
The majority of participants responded favorably to discussing heart disease risk
and management with a genetic counselor. Greater than 80% of participants indicated
that a genetic counselor would be helpful in discussing their risk for heart disease and
explaining genetic/genomic test results. In addition, 72.4% of participants indicated that
genetic counselors would be helpful in discussing heart disease management options.

30

This result is unsurprising as previous studies have shown that including a genetic
counselor in the process of reporting genomic test results is associated with positive
outcomes. One study found that when participants receive genomic risk information for
Type 2 Diabetes Mellitus from a genetic counselor, they report greater trust in the results
(Mills, Barry, & Haga, 2014). Although our work is prospective in nature, it supports the
claim that genetic counselors should be involved in the genomic medicine context. Most
participants also indicated that a cardiologist/other specialist and geneticist would be
helpful in explaining genomic test results and discussing medical management. This
result was expected as these two specialties are directly involved in the treatment of heart
disease and the interpretation of genetic results.
When presented with a hypothetical scenario where genetics alone increased the
participant’s risk for developing heart disease by 10%, respondents typically reported that
their intention of changing diet, taking prescription medications, and following up with a
specialist was between probable to neutral. The average likelihood of exercising
regularly was between very likely to probable. As 65.5% of participants were between
18-24 years of age and 51.7% had completed some college, it is possible that some of
these participants were student athletes or involved in intramural sports at the time of this
study. If this were the case, the finding that participants were more likely to regularly
exercising than make other lifestyle alterations is unsurprising. It is important to note
that the intention to positively alter one’s lifestyle is not equitable to actually
participating in actions that promote one’s health. Therefore, based on previous research,
it would be reasonable to hypothesize that presentation of personalized genomic
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information may not lead to lifestyle modifications, but may lead to engagement in
medical interventions, such as taking prescription medications (Kullo et al., 2016).
We also found that women are more likely to indicate an intention to alter diet
than men are. This result coincides with other literature. One study found that women
are more likely to adhere to healthy eating recommendations than men. In addition,
dieting is more common in women than men (Wardle et al., 2004).
When participants were asked how high their genetic risk would have to be to
make lifestyle modifications, we observed results that aligned with what we expected
based on their previous responses to questions determining the likelihood of engaging in
health-related behaviors. The percent genetic risk required for participants to be willing
to change diet, take prescription medications, and regularly follow-up with a specialist on
average fell between 40% to 50%. Participants typically reported the lowest percent
genetic risk required for them to be willing to exercise regularly. As respondents
indicated they were more likely to exercise regularly than to engage in any other healthpromoting behavior, this result was expected. There was a lot of spread between this
data, indicating there was little agreement between participants in terms of the value of
genetic risk that would result in behavioral changes. As perception of risk is a subjective
experience influenced by an assortment of factors (Veach, LeRoy, & Bartels, 2003), a
large variety of answers was expected.
In summation, this study found participants largely had low genetic literacy.
After viewing a genetic information video, a majority of participants perceived genomic
information to be useful in understanding their risk of developing heart disease. In
addition, they believed a genetic counselor would be helpful in explaining not only
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genomic test results, but also one’s risk for developing heart disease and medical
management options. Lastly, participants were typically most likely to indicate an
intention to exercise regularly if their risk for heart disease were increased because of
genetics. They were less likely to engage in diet modifications, take prescription
medications, or regularly follow-up with a specialist. This exploratory analysis provides
preliminary insight into how individuals with a family history of a complex disease
perceive genomic information. It also begins to assess from which healthcare providers
patients would like to receive this information from and how they will utilize this
information.
This study had some limitations. First, the results were based on the thoughts and
opinions of 29 participants. The study population was largely composed of young adults,
and all participants had at least some college education background. Therefore, these
results are not representative of larger, more diverse populations with differing ages and
education levels. In addition, although patients were invited to participate at a local
cardiology clinic and American Heart Association chapter, only one respondent was
affected with heart disease. These results may be different in a research project focusing
on the opinions of those affected with this condition. Lastly, it is possible that the sample
is primarily composed of highly motivated individuals, resulting in sampling bias
(Barratt, H. & Kirwan, M. 2009). If this occurred in the present study, the results would
not be representative of all individuals with a family history of heart disease.
Given these results, there are a number of directions future research can take. As
this study is a pilot study, assessing the perceived utility of genomic medicine in a larger
sample population would help researchers and clinicians better understand the general
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population’s thoughts and opinions on this newer field of medicine. In addition, in our
study, we saw that nearly all participants would share genetic risk information with their
doctor; however previous research has shown that not all patients disclose this
information with their healthcare provider (Gordon et al., 2011). It would be interesting
to explore what factors influence a patient’s decision to share their genetic risk
information with their physician.
A particularly informative future direction would be to do a qualitative analysis of
participants’ reasons for rating the likelihood to engage in health-related behaviors
differently. In our study, we observed that participants were most likely to exercise
regularly. It would be interesting to understand why changing diet, taking prescription
medications, and regularly following-up with a specialist were not rated as likely.
2.6 Conclusions
The focus of this study was to assess the perceived utility of personalized
genomic medicine in individuals with a family history of heart disease. We surveyed
individuals 18 years or older with at least one first-degree or two second-degree relatives
with heart disease. This exploratory research had four goals: to assess individuals’
baseline understanding of basic genetic knowledge and the genetic basis of heart disease,
to determine whether these individuals think personalized genomic medicine would be
helpful in assessing their risk for developing heart disease, to identify the genetic
counselor’s role in providing genomic risk information, and to determine whether
participants would intend to alter their lifestyle having learned that genetics increased
their risk of developing heart disease.
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We found that participants tended to overestimate the risk of both a heart attack
and atherosclerosis based on genetic factors. In addition, we found that on average,
respondents answered 2.793 of the six background genetic knowledge questions
correctly. This indicated that the baseline genetic literacy of this surveyed population
was rather low. All but one participant strongly agreed or agreed that genetic/genomic
information would be useful in understanding their risk of developing heart disease. This
result further adds to our knowledge of public perception of personalized genomic
medicine.
When asked about the genetic counselor’s role in discussing heart disease risk and
management, a majority of participants indicated genetic counselors would be helpful in
discussing their risk of developing heart disease, genetic/genomic test results, and
medical management options related to heart disease. This result illustrates that there is a
role for genetic counselors within a genomic medicine context and begins to define that
role.
Lastly, on average, participants indicated they were more likely to exercise
regularly than engage in other health promoting behaviors if they were told that genetics
alone increased their risk of developing heart disease by 10%. Participants tended to rate
the likelihood of altering diet, taking prescription medications, and regularly followingup with a specialist between probable to neutral. In addition, women were more likely to
indicate they would alter their diet than men. These results may help clinicians prioritize
which lifestyle modifications they will discuss with patients at risk for heart disease.
This study provides preliminary insight into how individuals with a family history
of a complex disease perceive and utilize genomic information and what the genetic
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counselor’s role will be within the genomic medicine context. Our results support the
expansion of genomic medicine from the perspective of a sample population at risk for a
multifactorial condition. In addition, they illustrate the importance of the genetic
counselor within this field. Participants overwhelmingly supported the assistance of a
genetic counselor in explaining risk for developing heart disease, explaining genomic test
results, and discussing management options. Genetic counselors will be pivotal in
interpreting, communicating, and contextualizing genomic information. As a
cardiologist/other specialist and geneticist were also considered by a majority of
participants to be helpful in this capacity, we stress the importance of a multidisciplinary
approach to genomic medicine. Our results also support the genetic counselor’s role in
discussing disease management options. As participants indicated they were most likely
to exercise regularly, a medical management discussion should emphasize the importance
of other lifestyle modifications, such as healthy eating, prescription medications, and
following up with specialists. A multidisciplinary team, that includes a genetic
counselor, will be beneficial in ensuring the patient receives and understands the
information they need to manage their health. An in-depth discussion about complex
disease management does not typically include a genetic counselor currently; therefore,
the genetic counselor scope of practice may expand within the genomic medicine context.
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Table 2.1 Participant Demographics
Participants
Preferred Gender
Male
Female
Prefer not to answer
Highest Education
Completed
Some college
2-year college
4-year college
Graduate school
Age
18 – 24
25 – 31
32 – 38
39 – 45
46 – 51
52 – 58
>59 years
Heart Disease Status
Affected
Unaffected

N=29

(%)

9
19
1

(31.0)
(65.5)
(3.4)

15
3
7
4

(51.7)
(10.3)
(24.1)
(13.8)

19
4
1
0
1
2
2

(65.5)
(13.8)
(3.4)
(0.0)
(3.4)
(6.9)
(6.9)

1
28

(3.4)
(96.6)

Table 2.2 Helpful Healthcare Providers for Discussing Test Results and
Management
Participants
(N=29)
28
21
13
6
1
1

Healthcare Providers
Cardiologist, or other specialist
Geneticist
Nutritionist
Nurse
Primary care physician
Sports medicine, physical therapy
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(%)
(96.6)
(72.4)
(44.8)
(20.7)
(3.4)
(3.4)

Table 2.3 Intention to Undergo Lifestyle Modifications

Change Diet
Exercise
Regularly
Take
Prescription
Medications
Follow-up
with a
Specialist

Very
Likely (%)
44.8
51.7

Probable
(%)
27.6
27.6

Neutral
(%)
6.9
13.8

Possible
(%)
17.2
3.4

Unlikely
(%)
3.4
3.4

41.4

24.1

24.1

6.9

3.4

48.3

17.2

13.8

13.8

3.4

Table 2.4 Genetic Risk Value Associated with Intention to Change Lifestyle

Change Diet
Exercise Regularly
Take Prescription
Medications
Follow-up with a
Specialist

Mean (%)
41.042
33.909
47.917

Standard Deviation (%)
21.698
24.102
26.137

44.250

23.988
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40

35

30

Percent

25

20

15

10

5

0
0

1
2
3
4
Number of Questions Answered Correctly

Figure 2.1 Background Genetic Knowledge
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Chapter 3. Conclusions
The focus of this study was to assess the perceived utility of personalized
genomic medicine in individuals with a family history of heart disease. We surveyed
individuals 18 years or older with at least one first-degree or two second-degree relatives
with heart disease. This exploratory research had four goals: to assess individuals’
baseline understanding of basic genetic knowledge and the genetic basis of heart disease,
to determine whether these individuals think personalized genomic medicine would be
helpful in assessing their risk for developing heart disease, to identify the genetic
counselor’s role in providing genomic risk information, and to determine whether
participants would intend to alter their lifestyle having learned that genetics increased
their risk of developing heart disease.
We found that participants tended to overestimate the risk of both a heart attack
and atherosclerosis based on genetic factors. In addition, we found that on average,
respondents answered 2.793 of the six background genetic knowledge questions
correctly. This indicated that the baseline genetic literacy of this surveyed population
was rather low. All but one participant strongly agreed or agreed that genetic/genomic
information would be useful in understanding their risk of developing heart disease. This
result further adds to our knowledge of public perception of personalized genomic
medicine.
When asked about the genetic counselor’s role in discussing heart disease risk and
management, a majority of participants indicated genetic counselors would be helpful in
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discussing their risk of developing heart disease, genetic/genomic test results, and
medical management options related to heart disease. This result illustrates that there is a
role for genetic counselors within a genomic medicine context and begins to define that
role.
Lastly, on average, participants indicated they were more likely to exercise
regularly than engage in other health promoting behaviors if they were told that genetics
alone increased their risk of developing heart disease by 10%. Participants tended to rate
the likelihood of altering diet, taking prescription medications, and regularly followingup with a specialist between probable to neutral. In addition, women were more likely to
indicate they would alter their diet than men. These results may help clinicians prioritize
which lifestyle modifications they will discuss with patients at risk for heart disease.
This study provides preliminary insight into how individuals with a family history
of a complex disease perceive and utilize genomic information and what the genetic
counselor’s role will be within the genomic medicine context. Our results support the
expansion of genomic medicine from the perspective of a sample population at risk for a
multifactorial condition. In addition, they illustrate the importance of the genetic
counselor within this field. Participants overwhelmingly supported the assistance of a
genetic counselor in explaining risk for developing heart disease, explaining genomic test
results, and discussing management options. Genetic counselors will be pivotal in
interpreting, communicating, and contextualizing genomic information. As a
cardiologist/other specialist and geneticist were also considered by a majority of
participants to be helpful in this capacity, we stress the importance of a multidisciplinary
approach to genomic medicine. Our results also support the genetic counselor’s role in
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discussing disease management options. As participants indicated they were most likely
to exercise regularly, a medical management discussion should emphasize the importance
of other lifestyle modifications, such as healthy eating, prescription medications, and
following up with specialists. A multidisciplinary team, that includes a genetic
counselor, will be beneficial in ensuring the patient receives and understands the
information they need to manage their health. An in-depth discussion about complex
disease management does not typically include a genetic counselor currently; therefore,
the genetic counselor scope of practice may expand within the genomic medicine context.
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Appendix B. Letter to Participants
Dear Potential Participant:
You are invited to participate in a graduate research study focusing on the genetic risks associated
with heart disease. I am a graduate student in the genetic counseling program at the University of
South Carolina School of Medicine. My research investigates the perceived usefulness of genetic
test results in individuals with a family history of heart disease. In order to participate, you must
have one first-degree relative with heart disease, such as a parent, sibling, or child, or two seconddegree relatives with heart disease, such as aunts, uncles, or grandparents. In addition, you must
be 18 years of age or older. The research involves completing an online questionnaire and
watching a short video.
The questionnaire will attempt to understand your baseline genetic knowledge, whether you
would find genomic testing to be useful in understanding your risk of developing heart disease
and which healthcare providers you would prefer receiving this information from, and whether
knowledge of the genetic risks associated with heart disease would result in any lifestyle
modifications. If you do not wish to answer a certain question, please skip that question and
continue with the rest of your questionnaire.
All responses gathered from the questionnaires will be kept anonymous and confidential. We
only ask for your email in order to enter that email address into a drawing to be chosen to receive
a $5 Amazon gift card. It is not necessary that you provide this information. The results of this
study might be published or presented at academic meetings; however, participants will not be
identified. If you are chosen for the drawing, your prize will be sent to you at a later date, after
having collected all data. Your contact information will not be used for any other purposes
beyond to send you the drawing prize if you have won.
Your participation in this research is voluntary. By completing this questionnaire, you are
consenting that you have read and understand this information. At any time, you may withdraw
from the study by not completing the questionnaire.
Thank you for your time and consideration to participate in this questionnaire. Your responses
may help members of the medical community better understand how those with a family history
of heart disease perceive the area of personalized genomic medicine and the topic of genomic test
results. If you have any questions regarding this research, you may contact myself or my faculty
adviser, Crystal Hill-Chapman, using the contact information below. If you have any questions
about your rights as a research participant, you may contact the Office of Research Compliance at
the University of South Carolina at (803)-777-7095.
Sincerely,
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Dana Mittag, BS
Genetic Counseling Intern
University of South Carolina
Genetic Counseling Program
2 Medical Park, Suite 208
Columbia, SC 29203
607-280-9858
dana.mittag@uscmed.sc.edu

Crystal Hill-Chapman, PhD
Thesis Director & Associate Professor
University of South Carolina
Genetic Counseling Program
2 Medical Park, Suite 208
Columbia, SC 29203
CHillChapman@fmarion.edu
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Appendix C. Questionnaire
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Appendix D. Participant Consent Agreement
We would like to invite individuals with a family history of heart disease to participate in
a study about the perceived usefulness of genetic information in regards to heart disease.
In order to participate, you must have one first-degree relative with heart disease, such as
a parent, sibling, or child, or two second-degree relatives with heart disease, such as
aunts, uncles, or grandparents. Your participation would be greatly appreciated, as your
opinions will increase our understanding of the usefulness of genetic information in
individuals with a family history of heart disease. We believe the results of this study
will aid members of the medical community in understanding how those with a family
history of heart disease perceive the area of personalized genomic medicine.
Your participation in the study is voluntary, and you can withdraw at any time.
Participation in the study involves completing an online questionnaire and watching a
short video. The questionnaire is anonymous, meaning that we will not collect any
personal information that could identify you or connect you to your responses. However,
if you are interested in being entered into a drawing for one of five, $5 Amazon gift
cards, you can include your email address at the end of the questionnaire. Your contact
information will not be used for any other purposes beyond sending you the drawing
prize if you have won. This questionnaire should take approximately 15 minutes to
complete. Questions in the questionnaire will attempt to understand your baseline
genetic knowledge, whether you would find genomic testing to be useful in
understanding your risk of developing heart disease and which healthcare providers you
would prefer receiving this information from, and whether knowledge of the genetic risks
associated with heart disease would result in any lifestyle modifications.
Dana Mittag, a genetic counseling student at the University of South Carolina Medical
School for a Master’s Thesis project, is conducting this study. Crystal Hill-Chapman, the
thesis director and an associate professor, is the faculty thesis advisor for this study. If
you have any questions about this study, please contact us.

Dana Mittag, BS
Genetic Counseling Intern
University of South Carolina
Genetic Counseling Program
2 Medical Park, Suite 208
Columbia, SC 29203
dana.mittag@uscmed.sc.edu

Crystal Hill-Chapman, PhD
Thesis Director & Associate Professor
University of South Carolina
Genetic Counseling Program
2 Medical Park, Suite 208
Columbia, SC 29203
CHillChapman@fmarion.edu

63

For questions about your rights as a participant, you may contact the Office of Research
Compliance at the University of South Carolina at 803-777-7095.
By clicking the “Next” button below, you are indicating your consent to participate in
this study. Thank you for sharing your insight.
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Appendix E. Script for Genetic Education Video
Heart disease, also known as cardiovascular disease, is a disorder affecting the
heart and blood vessels. As you may already know, many of the complications
associated with heart disease are due to a process called atherosclerosis, also called
coronary artery disease. Atherosclerosis occurs when a substance called plaque begins to
accumulate along the walls of the arteries. This will narrow the arteries, which will
restrict blood flow through these important vessels. Plaque will continue to build up over
time, and eventually a blood clot can form, substantially or completely blocking blood
flow. When a blood clot blocks blood flow to a portion of the heart, a heart attack
occurs. If blood flow is restricted completely as a result of a blood clot, part of the heart
will start to die [1][5].
It is known that coronary artery disease clusters in families. This means that
when we see patients with this type of heart disease, there are often other members of that
same family that are or were affected with the disease as well. Because we see this
clustering in families, it suggests that genetics plays a large role in causing this disease.
In fact, it is estimated that the genetic influence of both coronary artery disease and
myocardial infarction, also known as a heart attack, is between 50-60%. Another way to
look at this is genetic factors account for 50-60% of the risk for coronary artery disease
and heart attacks, with 40-50% of the risk being accounted for by other factors, such as
high blood pressure, diabetes, high cholesterol, lack of exercise, and obesity to name a
few [3].
Genomic tests can identify very small changes in DNA that are relatively
common in the general population. These changes are called single nucleotide
polymorphisms, or SNPs. It is estimated that certain well-known SNPs increase the risk
for coronary heart disease, also called coronary artery disease, by at least 10% [4].
One single gene condition associated with early-onset heart disease is familial
hypercholesterolemia (FH). We inherit two copies of our genes, one from mom and one
from dad. Some diseases are caused by changes in genes. Familial hypercholesterolemia
is a condition caused by changes in a gene that results in poor metabolism of a type of
cholesterol found in the body. When left untreated, it is approximated that those with a
change in just one copy of a gene associated with FH have a 20-fold increased chance for
CHD. Those affected with familial hypercholesterolemia have a 50% chance of passing
on the condition to their children [2][6].
So as you can see, estimating the genetic risk for heart disease is complicated. In
some conditions, like familial hypercholesterolemia, there is a defined genetic risk for
heart disease. The inheritance of the condition is well defined as those with the condition
having a 50% chance of passing that same condition down to their children. Other
genetic factors have a less well-defined risk associated with them, such as the wellknown SNPs, which are the small, common genetic changes, that can increase risk of
coronary heart disease by at least 10%. As we do more genomic testing and learn more
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about the genetics associated with heart disease, we will likely provide a better
personalized assessment of an individual’s risk for heart disease.
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